MedTrace Logo

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

NCT00853073 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2018-07-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.

Conditions

Interventions

DRUG

bevacizumab

1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure

OTHER

balanced salt solution

0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure

Sponsors & Collaborators

  • Wills Eye

    lead OTHER

Principal Investigators

  • Marlene R Moster, MD · Wills Eye

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00853073 on ClinicalTrials.gov